- Home
- MEGL vs INDP Comparison
MEGL vs INDP Comparison
Compare MEGL & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEGL
- INDP
- Stock Information
- Founded
- MEGL 2016
- INDP 2000
- Country
- MEGL Hong Kong
- INDP United States
- Employees
- MEGL N/A
- INDP N/A
- Industry
- MEGL Finance: Consumer Services
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- MEGL Finance
- INDP Health Care
- Exchange
- MEGL Nasdaq
- INDP Nasdaq
- Market Cap
- MEGL 7.0M
- INDP 5.0M
- IPO Year
- MEGL 2022
- INDP N/A
- Fundamental
- Price
- MEGL $1.52
- INDP $10.76
- Analyst Decision
- MEGL
- INDP Strong Buy
- Analyst Count
- MEGL 0
- INDP 2
- Target Price
- MEGL N/A
- INDP $8.50
- AVG Volume (30 Days)
- MEGL 3.1M
- INDP 689.1K
- Earning Date
- MEGL 07-07-2025
- INDP 08-11-2025
- Dividend Yield
- MEGL N/A
- INDP N/A
- EPS Growth
- MEGL N/A
- INDP N/A
- EPS
- MEGL N/A
- INDP N/A
- Revenue
- MEGL $1,645,862.00
- INDP N/A
- Revenue This Year
- MEGL N/A
- INDP N/A
- Revenue Next Year
- MEGL N/A
- INDP N/A
- P/E Ratio
- MEGL N/A
- INDP N/A
- Revenue Growth
- MEGL N/A
- INDP N/A
- 52 Week Low
- MEGL $1.02
- INDP $7.56
- 52 Week High
- MEGL $5.52
- INDP $66.64
- Technical
- Relative Strength Index (RSI)
- MEGL 49.86
- INDP 49.29
- Support Level
- MEGL $1.46
- INDP $8.71
- Resistance Level
- MEGL $1.85
- INDP $13.44
- Average True Range (ATR)
- MEGL 0.25
- INDP 2.05
- MACD
- MEGL -0.02
- INDP 0.25
- Stochastic Oscillator
- MEGL 8.60
- INDP 23.81
About MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.